TM9SF2 Antibody (Rabbit mAb) [L17H20]

Application: Reactivity: Mouse, Rat, Human

Usage Information

Dilution
WB1:1000 IHC1:2000 FCM1:150

Application
WB, IHC, FCM

Reactivity
Mouse, Rat, Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
76 kDa 55 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
TM9SF2 Antibody (Rabbit mAb) [L17H20] detects endogenous levels of total TM9SF2 protein.

Clone
L17H20

Synonym(s)
Transmembrane 9 superfamily member 2, p76, TM9SF2

Background
TM9SF2, or transmembrane 9 superfamily member 2, is a conserved nonaspanin family membrane protein characterized by nine predicted transmembrane segments and predominant localization to endosomal and Golgi-associated intracellular compartments, where it functions as a channel or small-molecule transporter that influences vesicle physiology and trafficking fidelity. TM9SF2 colocalizes with transferrin receptors and subsets of mannose 6‑phosphate receptors in endosomes rather than at the plasma membrane or classical Golgi cisternae, a distribution that aligns with its contribution to endosomal ion homeostasis and luminal pH regulation, thereby affecting cargo sorting and receptor recycling. TM9SF2 is part of a broader TM9SF network that modulates phagocytic uptake and actin cytoskeleton control and interacts with pattern-recognition receptors such as PGRP‑LC, suggesting roles in innate immune receptor positioning and in preventing inappropriate signaling from unstimulated receptors. In human colorectal cancer, approximately one third of patient tumors show elevated TM9SF2 mRNA, and loss of TM9SF2 reduces anchorage-independent growth and diminishes tumor fitness in vitro and in vivo, implicating this transporter-like protein as a positive regulator of malignant proliferation and survival. Transcriptome profiling of TM9SF2‑deficient colorectal cancer cells reveals altered expression of genes linked to cell-cycle progression, oxidative phosphorylation and ceramide signaling, pointing to a role for TM9SF2 in coupling endosomal/Golgi function to metabolic and stress pathways that support tumor growth. TM9SF2 is required for maintaining proper glycosylation in the Golgi: knockout cells exhibit reduced levels of glycosphingolipids such as globotriaosylceramide (Gb3) and display defective endosomal trafficking, indicating that TM9SF2 activity supports glycan synthesis and vesicular transport circuits that underlie membrane composition and receptor routing. These trafficking and glycosylation roles are relevant for host–pathogen interactions and toxin responses, as TM9SF2 has emerged as a host factor for multiple lethal pathogens and for ricin-induced cytotoxicity, where its contribution to Golgi integrity and endosomal transport influences toxin routing and cellular susceptibility.

Background

TM9SF2, or transmembrane 9 superfamily member 2, is a conserved nonaspanin family membrane protein characterized by nine predicted transmembrane segments and predominant localization to endosomal and Golgi-associated intracellular compartments, where it functions as a channel or small-molecule transporter that influences vesicle physiology and trafficking fidelity. TM9SF2 colocalizes with transferrin receptors and subsets of mannose 6‑phosphate receptors in endosomes rather than at the plasma membrane or classical Golgi cisternae, a distribution that aligns with its contribution to endosomal ion homeostasis and luminal pH regulation, thereby affecting cargo sorting and receptor recycling. TM9SF2 is part of a broader TM9SF network that modulates phagocytic uptake and actin cytoskeleton control and interacts with pattern-recognition receptors such as PGRP‑LC, suggesting roles in innate immune receptor positioning and in preventing inappropriate signaling from unstimulated receptors. In human colorectal cancer, approximately one third of patient tumors show elevated TM9SF2 mRNA, and loss of TM9SF2 reduces anchorage-independent growth and diminishes tumor fitness in vitro and in vivo, implicating this transporter-like protein as a positive regulator of malignant proliferation and survival. Transcriptome profiling of TM9SF2‑deficient colorectal cancer cells reveals altered expression of genes linked to cell-cycle progression, oxidative phosphorylation and ceramide signaling, pointing to a role for TM9SF2 in coupling endosomal/Golgi function to metabolic and stress pathways that support tumor growth. TM9SF2 is required for maintaining proper glycosylation in the Golgi: knockout cells exhibit reduced levels of glycosphingolipids such as globotriaosylceramide (Gb3) and display defective endosomal trafficking, indicating that TM9SF2 activity supports glycan synthesis and vesicular transport circuits that underlie membrane composition and receptor routing. These trafficking and glycosylation roles are relevant for host–pathogen interactions and toxin responses, as TM9SF2 has emerged as a host factor for multiple lethal pathogens and for ricin-induced cytotoxicity, where its contribution to Golgi integrity and endosomal transport influences toxin routing and cellular susceptibility.

References
https://pubmed.ncbi.nlm.nih.gov/25139117/ https://pubmed.ncbi.nlm.nih.gov/30333512/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%